Novel Compound Beneficial as Adjunct to Antibody-Based Therapy for Stage IV NSCLC Patients

Article Information

DOI 
http://dx.doi.org/10.1177/1559897715588496
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2015 SAGE Publications

Author Information

  1. Anita Misra-Press, PhD
  1. Ada Braun, MD, PhD
    1. Biothera, Eagan, Minnesota, USA
View Full Text

Article usage

AbstractFullPDF
May 20152133
Jun 2015600
Jul 2015600
Aug 20152600
Sep 20159800
Oct 2015532
Nov 20156032
Total22297

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Novel Compound Beneficial as Adjunct to Antibody-Based Therapy for Stage IV NSCLC Patients
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

non–small cell lung cancer
stage IV
PGG beta-glucan
bevacizumab, immune cell modulator
carboplatin/paclitaxel
Oncology Clinical Trials